Clinicopathologic and survival differences between adenocarcinoma of the distal oesophagus and gastro-oesophageal junction.
adenocarcinoma
gastro-oesophageal junction cancer
oesophageal cancer
survival
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
01
05
2022
received:
26
02
2022
accepted:
16
05
2022
pubmed:
1
6
2022
medline:
15
9
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
The incidence of adenocarcinoma of the distal oesophagus (DO) and gastro-oesophageal junction (GOJ) are increasing. They may represent differing disease processes. This study aimed to assess clinicopathological and survival differences between patients with DO and GOJ adenocarcinomas. Data were extracted from a prospective single-surgeon database of consecutive patients undergoing an open Ivor-Lewis oesophagectomy for oesophageal adenocarcinoma (distal oesophagus, Siewert type I and II). Differences in clinicopathological characteristics and survival were evaluated and prognostic factors examined using univariate and multivariate survival analyses. The data were available for 234 patients who underwent an oesophagectomy between 1992 and 2019. DO tumours had higher rates of Barrett's oesophagus (P < 0.001), presented with lower tumour stage (P = 0.02) and were more likely to be associated with fewer lymph nodes resected (P = 0.003) than GOJ tumours. The median overall survival for distal oesophageal tumours was 29.2 months, while gastro-oesophageal tumours was 38.6 months. Kaplan Meier analysis did not show a difference in overall survival between the two groups (P = 0.08). However, when adjusted for potential confounders, GOJ tumours were associated with a reduced adjusted hazard of death (adjusted HR 0.58, 95% CI 0.36-0.92, P = 0.022) compared with DO tumours. This study suggests that GOJ cancers have different clinicopathological characteristics and improved survival compared to DO tumours.
Sections du résumé
BACKGROUND
The incidence of adenocarcinoma of the distal oesophagus (DO) and gastro-oesophageal junction (GOJ) are increasing. They may represent differing disease processes. This study aimed to assess clinicopathological and survival differences between patients with DO and GOJ adenocarcinomas.
METHODS
Data were extracted from a prospective single-surgeon database of consecutive patients undergoing an open Ivor-Lewis oesophagectomy for oesophageal adenocarcinoma (distal oesophagus, Siewert type I and II). Differences in clinicopathological characteristics and survival were evaluated and prognostic factors examined using univariate and multivariate survival analyses.
RESULTS
The data were available for 234 patients who underwent an oesophagectomy between 1992 and 2019. DO tumours had higher rates of Barrett's oesophagus (P < 0.001), presented with lower tumour stage (P = 0.02) and were more likely to be associated with fewer lymph nodes resected (P = 0.003) than GOJ tumours. The median overall survival for distal oesophageal tumours was 29.2 months, while gastro-oesophageal tumours was 38.6 months. Kaplan Meier analysis did not show a difference in overall survival between the two groups (P = 0.08). However, when adjusted for potential confounders, GOJ tumours were associated with a reduced adjusted hazard of death (adjusted HR 0.58, 95% CI 0.36-0.92, P = 0.022) compared with DO tumours.
CONCLUSION
This study suggests that GOJ cancers have different clinicopathological characteristics and improved survival compared to DO tumours.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2137-2142Informations de copyright
© 2022 Royal Australasian College of Surgeons.
Références
Hsu A, Zayac AS, Eturi A, Almhanna K. Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. Ann Transl Med. 2020; 8: 1109.
Oo AM, Ahmed S. Overview of gastroesophageal junction cancers. Mini-invasive. Surgery 2019; 3: 13.
Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021; 5: 46-59.
Bai J-G, Lv Y, Dang C-X. Adenocarcinoma of the esophagogastric junction in China according to Siewert's classification. Jpn. J. Clin. Oncol. 2006; 36: 364-7.
Curtis NJ, Noble F, Bailey IS, Kelly JJ, Byrne JP, Underwood TJ. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J. Surg. Oncol. 2014; 109: 202-7.
Hosokawa Y, Kinoshita T, Konishi M et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann. Surg. Oncol. 2012; 19: 677-83.
Mukaisho K, Nakayama T, Hagiwara T, Hattori T, Sugihara H. Two distinct etiologies of gastric cardia adenocarcinoma: interactions among pH, helicobacter pylori, and bile acids. Front. Microbiol. 2015; 6: 412.
Bartel M, Brahmbhatt B, Bhurwal A. Incidence of gastroesophageal junction cancer continues to rise: analysis of surveillance, epidemiology, and end results (SEER) database. J. Clin. Oncol. 2019; 37: 40.
Goto H, Tokunaga M, Miki Y et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric Cancer 2015; 18: 375-81.
Ajani JA, D'Amico TA, Bentrem DJ et al. Esophageal and Esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 2019; 17: 855-83.
Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the siewert classification on the outcome of patients treated by preoperative chemoradiotherapy for a nonmetastatic adenocarcinoma of the oesophagogastric junction. Gastroenterol. Res. Pract. 2015; 2015: 1-9.
Ustaalioğlu BBÖ, Tilki M, Sürmelioğlu A et al. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification. Turk. J. Surg. 2017; 33: 18-24.
Demicco EG, Farris AB 3rd, Baba Y et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod. Pathol. 2011; 24: 1177-90.
Peyre CG, Hagen JA, DeMeester SR et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann. Surg. 2008; 248: 979-85.
Rizk NP, Ishwaran H, Rice TW et al. Optimum lymphadenectomy for esophageal cancer. Ann. Surg. 2010; 251: 46-50.
Kelty CJ, Kennedy CW, Falk GL. Ratio of metastatic lymph nodes to total number of nodes resected is prognostic for survival in esophageal carcinoma. J. Thorac. Oncol. 2010; 5: 1467-71.
Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.
Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017; 67: 304-17.
Rice TW, Apperson-Hansen C, DiPaola LM et al. Worldwide esophageal cancer collaboration: clinical staging data. Dis. Esophagus 2016; 29: 707-14.
Straatman J, van der Wielen N, Cuesta MA et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann. Surg. 2017; 266: 232-6.
Ito H, Clancy TE, Osteen RT et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J. Am. Coll. Surg. 2004; 199: 880-6.
Jezerskyte E, Mertens AC, van Dieren S et al. Gastrectomy versus Esophagectomy for gastroesophageal junction tumors: short- and long-term outcomes from the Dutch upper GI cancer audit. Ann. Surg. 2020. https://doi.org/10.1097/SLA.0000000000004610.
Kamarajah SK, Phillips AW, Griffiths EA, Ferri L, Hofstetter WL, Markar SR. Esophagectomy or Total gastrectomy for Siewert 2 gastroesophageal junction (GEJ) adenocarcinoma? A registry-based analysis. Ann Surg Oncol. 2021; 28: 8485-94.